Data / Drug companies / Upsher-Smith Laboratories, LLC
Upsher-Smith Laboratories, LLC: 102 products in the FDA NDC directory, labeler code 0832
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Upsher-Smith Laboratories, LLC (labeler code 0832) lists 102 products in the FDA National Drug Code Directory, covering 38 finished drugs by generic name. By type: 102 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on September 8, 2026.
The request: Watch Upsher-Smith Laboratories, LLC (FDA labeler code 0832): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 0832
- Products in commercial distribution
- 102
- Packages
- 177
- Finished drugs by generic name
- 38
- Prescription products
- 102
- Over the counter products
- 0
- Controlled substance products
- Schedule II 9, Schedule III 2, Schedule IV 2
- Flagged as original packager
- 84 of 84 products that carry the flag
- Started marketing in the last 12 months
- 6
- Products with a marketing end date set
- 31
- Earliest marketing start
- April 17, 1986
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 93 | 91.2% |
| Authorized generics (NDA) | 7 | 6.9% |
| New drug applications (NDA) | 2 | 2% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 102 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Morphine sulfate | 9 | 31 |
| Warfarin sodium | 9 | 16 |
| Haloperidol | 6 | 32 |
| Topiramate | 5 | 56 |
| Chlorpromazine hydrochloride | 5 | 27 |
| Deflazacort | 4 | 11 |
| Doxazosin mesylate | 4 | 12 |
| Potassium chloride | 4 | 84 |
| Fluphenazine hydrochloride | 4 | 29 |
| Bethanechol chloride | 4 | 6 |
| Isotretinoin | 4 | 16 |
| Pitavastatin calcium | 3 | 10 |
| Propafenone hydrochloride | 3 | 15 |
| Carbamazepine | 3 | 52 |
| Divalproex sodium | 3 | 48 |
| Brimonidine tartrate | 2 | 15 |
| Fluvoxamine maleate | 2 | 16 |
| Methimazole | 2 | 23 |
| Amantadine hydrochloride | 2 | 32 |
| Imatinib mesylate | 2 | 17 |
| Memantine hydrochloride | 2 | 36 |
| Testosterone | 2 | 22 |
| Glatiramer acetate injection | 2 | 1 |
| Clobazam | 2 | 18 |
| Difluprednate | 1 | 6 |
| Exemestane | 1 | 12 |
| Brimonidine tartrate and timolol maleate | 1 | 14 |
| Ethacrynic acid | 1 | 10 |
| Mesalamine | 1 | 41 |
| Valproic acid | 1 | 21 |
| Ciprofloxacin hydrochloride and dexamethasone | 1 | 1 |
| Bexarotene | 1 | 8 |
| Moxifloxacin hydrochloride | 1 | 20 |
| Ramelteon | 1 | 29 |
| Fluoxetine hydrochloride | 1 | 44 |
| Famotidine | 1 | 138 |
| Oxybutynin chloride | 1 | 45 |
| Nystatin | 1 | 40 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 42 | 41.2% |
| Capsule, extended release | 18 | 17.6% |
| Tablet, film coated | 12 | 11.8% |
| Tablet, extended release | 5 | 4.9% |
| Capsule, liquid filled | 4 | 3.9% |
| Solution/ drops | 3 | 2.9% |
| Tablet, delayed release | 3 | 2.9% |
| Tablet, film coated, extended release | 2 | 2% |
| Capsule | 2 | 2% |
| Injection, solution | 2 | 2% |
| Emulsion | 1 | 1% |
| Capsule, gelatin coated | 1 | 1% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Brimonidine Tartrate | 0832-1435 | Solution/ drops | Generic drugs (ANDA) | September 8, 2026 |
| Fluvoxamine Maleate | 0832-6026 | Capsule, extended release | Generic drugs (ANDA) | May 15, 2026 |
| Fluvoxamine Maleate | 0832-6025 | Capsule, extended release | Generic drugs (ANDA) | April 30, 2026 |
| Glatiramer Acetate | 0832-6085 | Injection, solution | Generic drugs (ANDA) | January 23, 2026 |
| Glatiramer Acetate | 0832-6084 | Injection, solution | Generic drugs (ANDA) | January 23, 2026 |
| Ciprofloxacin and Dexamethasone | 0832-1430 | Suspension | Generic drugs (ANDA) | January 6, 2026 |
| Difluprednate | 0832-6054 | Emulsion | Generic drugs (ANDA) | February 21, 2025 |
| Deflazacort | 0832-0817 | Tablet | Generic drugs (ANDA) | November 5, 2024 |
| Deflazacort | 0832-0816 | Tablet | Generic drugs (ANDA) | November 5, 2024 |
| Deflazacort | 0832-0815 | Tablet | Generic drugs (ANDA) | November 5, 2024 |
| Deflazacort | 0832-0814 | Tablet | Generic drugs (ANDA) | November 5, 2024 |
| Brimonidine Tartrate | 0832-1420 | Solution/ drops | Generic drugs (ANDA) | June 12, 2024 |
| Imatinib mesylate | 0832-0533 | Tablet | Generic drugs (ANDA) | May 17, 2024 |
| Imatinib mesylate | 0832-0532 | Tablet | Generic drugs (ANDA) | May 17, 2024 |
| Pitavastatin | 0832-6050 | Tablet | Generic drugs (ANDA) | November 2, 2023 |
| Pitavastatin | 0832-6049 | Tablet | Generic drugs (ANDA) | November 2, 2023 |
| Pitavastatin | 0832-6048 | Tablet | Generic drugs (ANDA) | November 2, 2023 |
| Famotidine | 0832-6045 | Powder, for suspension | Generic drugs (ANDA) | June 16, 2023 |
| Mesalamine | 0832-6056 | Capsule, extended release | Generic drugs (ANDA) | June 6, 2023 |
| Brimonidine Tartrate and Timolol Maleate | 0832-1425 | Solution/ drops | Generic drugs (ANDA) | December 15, 2022 |
| Fluphenazine Hydrochloride | 0832-6006 | Tablet, film coated | Generic drugs (ANDA) | November 22, 2022 |
| Fluphenazine Hydrochloride | 0832-6005 | Tablet, film coated | Generic drugs (ANDA) | November 22, 2022 |
| Fluphenazine Hydrochloride | 0832-6004 | Tablet, film coated | Generic drugs (ANDA) | November 22, 2022 |
| Fluphenazine Hydrochloride | 0832-6003 | Tablet, film coated | Generic drugs (ANDA) | November 22, 2022 |
| Fluoxetine hydrochloride | 0832-6032 | For solution | Generic drugs (ANDA) | November 15, 2022 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.